 |
|
|
| |
DISCOVER: 96-Week Follow-up of Black and
Hispanic/Latinx Study Participants
|
| |
| |
CROI 2020 March 9
Reported by Jules Levin
Edwin DeJesus1, Jason Halperin2, Indira Brar3, Eric Daar4, Jeffrey L. Stephens5, Yongwu Shao,6Lijie Zhong,6Ramin Ebrahimi,6Staci Bush,6Jonathon Anderson,6Moupali Das,6Scott McCallister,6Jeffrey H. Burack,7Michelle Iandiorio,8Gordon Crofoot9
1Orlando Immunology Center, Orlando, FL; 2CrescentCare, New Orleans, LA; 3Henry Ford Hospital, Detroit, MI; 4Harbor–UCLA Medical Center, Torrance, CA; 5Mercer University, Macon, GA; 6Gilead Sciences, Inc., Foster City, CA; 7East Bay AIDS Center, Oakland, CA; 8The University of New Mexico, Albuquerque; 9Crofoot Research Center, Houston, TX
CROI2019: THE PHASE 3 DISCOVER STUDY: DAILY F/TAF OR F/TDF FOR HIV PREEXPOSURE PROPHYLAXIS
http://www.natap.org/2019/CROI/croi_21.htm
EACS2019: Phase 3 Randomized, Controlled DISCOVER Study of Daily F/TAF or F/TDF for HIV Pre-exposure Prophylaxis: Week 96 Results
http://www.natap.org/2019/EACS/EACS_50.htm
IAS2019 Mexico City: DISCOVER STUDY for
HIV Pre-Exposure Prophylaxis:
F/TAF has a more Rapid Onset and
Longer Sustained Duration of HIV Protection Compared with F/TDF
http://www.natap.org/2019/IAS/IAS_08.htm
IDWeek 2019: Bone Safety Outcomes With F/TAF vs F/TDF for PrEP in the DISCOVER Trial
http://www.natap.org/2019/IDWeek/IDWeek_26.htm
IDWeek 2019: Renal Outcomes for Participants Taking F/TAF
versus F/TDF for HIV PrEP in the DISCOVER Trial
http://www.natap.org/2019/IDWeek/IDWeek_39.htm
EACS 2019: DISCOVER in Europe: a Subanalysis of the Phase 3, Randomized, Controlled Trial of Daily Emtricitabine/Tenofovir Alafenamide or Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Pre-exposure Prophylaxis
http://www.natap.org/2019/EACS/EACS_47.htm
|
| |
|
|
|
|
|
